This study evaluated the efficacy and safety of canagliflozin , a sodium glucose co-transporter 2 inhibitor , in patients with type 2 diabetes mellitus ( T2DM ) and within a subset of Stage 3 chronic kidney disease ( CKD ; estimated glomerular filtration rate [ eGFR ] 30 and < 50 ml/min/1 .73 m ( 2 ) ) .